Hu Yue, Deng Fang, Zhang Lupeng, Hu Keyue, Liu Shiqi, Zhong Suye, Yang Jun, Zeng Xiaomin, Peng Xiaoning
Department of Clinical Medicine, Hunan Normal University School of Medicine, 371 Tongzipo Road, Changsha 410006, China.
Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, 238 Shangmayuanling Lane, Changsha 410078, China.
J Clin Med. 2022 Aug 17;11(16):4811. doi: 10.3390/jcm11164811.
In patients with gliomas, depression is a common complication that may cause severe psychological barriers and deteriorate the patient's quality of life (QoL). Currently, the Hospital Anxiety and Depression Scale (HADS) is the most commonly used tool to diagnose depression in patients with gliomas. Female sex, unmarried status, low education level, high tumor grade, and a history of mental illness may increase the risks of depression and depressive symptoms in patients with gliomas. The QoL of patients with gliomas can be directly reduced by depression. Therefore, the evaluation and intervention of mood disorders could improve the overall QoL of patients with gliomas. Antidepressant use has become a treatment strategy for patients with gliomas and comorbid depression. This narrative review summarizes the current issues related to depression in patients with gliomas, including the prevalence, risk factors, and diagnostic criteria of depression as well as changes in QoL caused by comorbid depression and antidepressant use. The purpose of this review is to guide clinicians to assess the psychological status of patients with gliomas and to provide clinicians and oncologists with a new treatment strategy to improve the prognosis of such patients.
在胶质瘤患者中，抑郁是一种常见的并发症，可能会导致严重的心理障碍并使患者的生活质量（QoL）恶化。目前，医院焦虑抑郁量表（HADS）是诊断胶质瘤患者抑郁最常用的工具。女性、未婚状态、低教育水平、高肿瘤分级和精神疾病史可能会增加胶质瘤患者抑郁及抑郁症状的风险。抑郁会直接降低胶质瘤患者的生活质量。因此，对情绪障碍的评估和干预可以改善胶质瘤患者的整体生活质量。使用抗抑郁药已成为胶质瘤合并抑郁患者的一种治疗策略。这篇叙述性综述总结了目前与胶质瘤患者抑郁相关的问题，包括抑郁的患病率、危险因素、诊断标准以及合并抑郁和使用抗抑郁药所导致的生活质量变化。本综述的目的是指导临床医生评估胶质瘤患者的心理状态，并为临床医生和肿瘤学家提供一种改善此类患者预后的新治疗策略。
